ERCICEK, Fatma; HARSCOAT-SCHIAVO, Christelle; MARCHIVIE, Mathieu; MARRE, Samuel; SUBRA-PATERNAULT, Pascale

Chimie et Biologie des Membranes et des Nanoobjets [CBMN]

HARSCOAT-SCHIAVO, Christelle
Chimie et Biologie des Membranes et des Nanoobjets [CBMN]

MARCHIVIE, Mathieu

Idioma

Communication dans un congrès

Este ítem está publicado en

27th International Workshop on Industrial Crystallization, 2022-08-31, Espoo. 2022-08-31

Resumen en inglés

Co-crystalline products are becoming increasingly important in the pharmaceutical industry, due to the chirality, low water solubility and low bioavailability of most active pharmaceutical ingredients (API). Solids with a single crystalline phase composed of two entities (API + coformer COF) linked via non-covalent interactions are called co-crystals. The modification of the API crystal lattice through the incorporation of the COF enhances the physicochemical properties of the initial drug without altering its therapeutic purposes. Thus, understanding crystallization processes can help to obtain products with desired properties. The formation of metastable conglomerates by co-crystallization can be a solution for optical resolution< Leer menos

Palabras clave en inglés

Co-crystallization

Supercritical CO2

Chiral resolution

In-situ observations

Microfluidics

URI

https://oskar-bordeaux.fr/handle/20.500.12278/199208

Proyecto ANR

Apport du CO2 dans le contrôle de phase cristalline - ANR-18-CE07-0047

Centros de investigación

CBMN : Chimie & de Biologie des Membranes & des Nano-objets - UMR 5248

Ver/Abrir

Metadatos

Compartir este ítem

Licencia de uso del documento

Investigations of pharmaceutical compounds co-crystallization for application to chiral resolution assisted by supercritical CO2